Eli Lilly and Company Overview
Pro stress-test →Eli Lilly has entered the trillion-dollar market cap club, projecting record 2026 revenue of $80-$83 billion driven by insatiable global demand for its dual-agonist metabolic treatments, Mounjaro and Zepbound. This represents a staggering 25% year-over-year growth, signaling that the obesity and diabetes market is still in its early innings of expansion.
Strategic Profile
Pro stress-test →By controlling both the clinical development and the massive manufacturing infrastructure required to deliver metabolic treatments, Lilly has built a business model that is currently unrivaled in the industry. The company leverages its first-mover advantage and superior manufacturing scale to command over 60% of the metabolic health market share, with a multi-modal portfolio ranging from injectable tirzepatide to oral pills and the upcoming triple-agonist retatrutide.
Competitive Landscape
Pro stress-test →Novo Nordisk has emerged as a temporary loser, projecting a 5-13% decline in 2026 sales due to intense pricing competition and production bottlenecks. Eli Lilly's superior manufacturing scale, diverse portfolio, and first-mover advantage in the GLP-1 space create significant competitive barriers. Other key competitors include Merck and AstraZeneca in diabetes/obesity segments.
Industry Context
Eli Lilly and Company operates in Biopharmaceutical/Pharmaceutical Manufacturing & Distribution.
Key facts
Founded: 1876 · Headquarters: Indianapolis, US · Employees: N/A · Revenue: $59.4B (TTM) · Market cap: $975B